Citation index
Juan P. Frias, MD
Velocity Clinical Research, Los Angeles
Endocrinologist and clinical researcher whose published work spans phase II and phase III trials of incretin and dual incretin therapeutics for type 2 diabetes and obesity.
Public profiles
Cited on Peptides Research Hub
- Tirzepatide: research, pharmacology, and clinical evidence
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for T2DM (Mounjaro) and chronic weight management (Zepbound). This pillar covers mechanism, half-life, bioavailability, pivotal trials, safety, and regulatory status.
- Tirzepatide Safety Profile and Adverse Events in the Literature
Tirzepatide
This article summarizes adverse events from the SURPASS and SURMOUNT trial programs, the FDA boxed warning for thyroid C-cell tumors, and known cautions in pancreatitis, gallbladder disease, gastroparesis, and pregnancy.